These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 2445259)

  • 1. Elevated serotonin and reduced dopamine in subregionally divided Huntington's disease striatum.
    Kish SJ; Shannak K; Hornykiewicz O
    Ann Neurol; 1987 Sep; 22(3):386-9. PubMed ID: 2445259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.
    Kish SJ; Tong J; Hornykiewicz O; Rajput A; Chang LJ; Guttman M; Furukawa Y
    Brain; 2008 Jan; 131(Pt 1):120-31. PubMed ID: 17956909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective subregional dopamine depletions in the rat caudate-putamen following nigrostriatal lesions.
    Pehek EA; Crock R; Yamamoto BK
    Synapse; 1992 Apr; 10(4):317-25. PubMed ID: 1374937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of striatal histamine H2 receptors in Huntington's chorea but not in Parkinson's disease: comparison with animal models.
    Martínez-Mir MI; Pollard H; Moreau J; Traiffort E; Ruat M; Schwartz JC; Palacios JM
    Synapse; 1993 Nov; 15(3):209-20. PubMed ID: 7904088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine and homovanillic acid concentrations in striatal and limbic regions of human brain.
    Walsh FX; Stevens TJ; Langlais PJ; Bird ED
    Ann Neurol; 1982 Jul; 12(1):52-5. PubMed ID: 7114818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Striatal dopamine and homovanillic acid in Huntington's disease.
    Reynolds GP; Garrett NJ
    J Neural Transm; 1986; 65(2):151-5. PubMed ID: 2939198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of subchronic exposure to styrene on the extracellular and tissue levels of dopamine, serotonin and their metabolites in rat brain.
    Gagnaire F; Chalansonnet M; Carabin N; Micillino JC
    Arch Toxicol; 2006 Oct; 80(10):703-12. PubMed ID: 16518643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonin and dopamine striatal innervation in Parkinson's disease and Huntington's chorea.
    Bédard C; Wallman MJ; Pourcher E; Gould PV; Parent A; Parent M
    Parkinsonism Relat Disord; 2011 Sep; 17(8):593-8. PubMed ID: 21664855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.
    Suzuki M; Desmond TJ; Albin RL; Frey KA
    Synapse; 2001 Sep; 41(4):329-36. PubMed ID: 11494403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aging and the nigrostriatal dopamine system: a non-human primate study.
    Irwin I; DeLanney LE; McNeill T; Chan P; Forno LS; Murphy GM; Di Monte DA; Sandy MS; Langston JW
    Neurodegeneration; 1994 Dec; 3(4):251-65. PubMed ID: 7531106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease.
    Augood SJ; Faull RL; Emson PC
    Ann Neurol; 1997 Aug; 42(2):215-21. PubMed ID: 9266732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the levels of dopamine, serotonin and their metabolites in the caudate nucleus of the rat.
    Russ H; Henning K; Eckhardt H; Przuntek H
    Arzneimittelforschung; 1985; 35(2):481-2. PubMed ID: 2581589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography of striatal serotonin transporters in Parkinson disease.
    Kerenyi L; Ricaurte GA; Schretlen DJ; McCann U; Varga J; Mathews WB; Ravert HT; Dannals RF; Hilton J; Wong DF; Szabo Z
    Arch Neurol; 2003 Sep; 60(9):1223-9. PubMed ID: 12975287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurochemical effects of the endocannabinoid uptake inhibitor UCM707 in various rat brain regions.
    de Lago E; Ortega-Gutiérrez S; Ramos JA; López Rodríguez ML; Fernández-Ruiz J
    Life Sci; 2007 Feb; 80(10):979-88. PubMed ID: 17173937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
    Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression.
    Mathews TA; Fedele DE; Coppelli FM; Avila AM; Murphy DL; Andrews AM
    J Neurosci Methods; 2004 Dec; 140(1-2):169-81. PubMed ID: 15589347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unilateral destruction of dopamine pathways increases ipsilateral striatal serotonin turnover in rats.
    Karstaedt PJ; Kerasidis H; Pincus JH; Meloni R; Graham J; Gale K
    Exp Neurol; 1994 Mar; 126(1):25-30. PubMed ID: 7512513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss.
    Kish SJ; Rajput A; Gilbert J; Rozdilsky B; Chang LJ; Shannak K; Hornykiewicz O
    Ann Neurol; 1986 Jul; 20(1):26-31. PubMed ID: 2874765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amantadine enhances dopamine and serotonin turnover in the MPTP model of Parkinson's disease.
    Altagracia M; Rojas P; Kravzov J; Rios C
    Proc West Pharmacol Soc; 1993; 36():289-91. PubMed ID: 7690973
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.